Tgtx Stock Quote Overview and Analyst Forecast

If you're looking to stay on top of the latest developments with TGTX stock, let's take a closer look at the current stock quote overview and analyst forecast.

TGTX stock has been on a rollercoaster ride, with its price fluctuating significantly over the past year. The stock's current price is around $10.50 per share.

Analysts have been closely watching TGTX stock, and their forecasts are worth paying attention to. According to recent estimates, the company's revenue is expected to grow by 25% in the next quarter.

This growth is being driven by the company's innovative products and expanding customer base.

TG Therapeutics has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where Chairman and CEO Michael S. Weiss will deliver a presentation on Monday, January 13, 2025.

Investors and interested parties can access a live webcast of the presentation through the company's website.

The presentation will be made available on the company's website following the event for those who can't attend live.

TG Therapeutics will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Michael S. Weiss, the company's Chairman and CEO, will present at the conference.

The conference will take place on Monday, January 13, 2025, at 4:30 PM PT. A live webcast of the presentation will be available on the company's website for investors and interested parties.

The company's presentation will be made available on replay on the website following the event.

FUJIFILM Diosynth Biotechnologies has signed a manufacturing supply agreement with TG Therapeutics.

The Holly Springs, North Carolina site will provide security of supply for a B-cell therapy for relapsing multiple sclerosis.

This agreement will ensure a stable supply of the treatment, which is a significant step forward for patients with this condition.

The Holly Springs site will be responsible for manufacturing the therapy, providing a secure and reliable source for TG Therapeutics.

TG Therapeutics has seen significant price fluctuations over the past year, with a 1 Year Change of 106.86%.

The company's share price has also experienced considerable volatility, with a 52 Week High of $36.84 and a 52 Week Low of $12.84.

Here are the key price performance metrics:

The company's beta of 2.24 indicates that its stock price is relatively volatile compared to the overall market.

TG Therapeutics' Q3 earnings showed revenue growth, but shares fell due to missing EPS expectations.

Higher non-cash compensation and increased R&D investments contributed to the missed earnings.

Briumvi's revenue growth was a highlight, but it wasn't enough to offset the company's other expenses.

TG Therapeutics has seen significant growth in its share price over the past few years, with a 5-year change of 120.43%. This is a notable increase, but it's essential to consider the company's performance over different time periods.

The current share price is US$33.45, which is a 2.83% increase from the previous month. This is a relatively modest gain, but it's part of a larger trend.

Here are the key changes in TG Therapeutics' share price over the past year:

These numbers demonstrate the company's impressive growth, but it's also worth noting that the share price has been volatile in the past. The 52-week high was US$36.84, while the 52-week low was US$12.84.

Let's take a look at the financial information for TGTX stock. The company has a cash-to-debt ratio of 1.34, which is a relatively healthy position.

TGTX's debt-to-equity ratio is 1.32, indicating that the company's debt is substantial compared to its equity. The debt-to-EBITDA ratio is 42.64, which is a significant burden on the company's operations.

Here are some key financial metrics for TGTX:

The company's beta is 2.77, indicating a relatively high level of volatility in its stock price. The 14-Day RSI is 61.71, suggesting that the stock is currently in a neutral position.

When it comes to evaluating the financial performance of a company, one key metric to consider is shareholder returns. In the case of TG Therapeutics, the company has delivered impressive returns to its shareholders.

TGTX, the ticker symbol for TG Therapeutics, has returned 106.9% over the past year, significantly outperforming the US Biotechs industry which returned -4.3% over the same period.

The company's 7-day return of 12.0% also outpaces the US Biotechs industry's 4.2% return during the same timeframe.

Here's a comparison of TGTX's returns to the US Biotechs industry and the US Market:

TGTX's impressive returns have been driven by the company's successful commercialization of BRIUMVI, an anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis. The company's revenue from BRIUMVI has been substantial, with $89 million in U.S. net revenue generated in 2023.

Financial Strength is crucial for any company's long-term success. A company with a strong financial foundation can weather economic downturns and capitalize on growth opportunities.

Cash-to-Debt ratio is a key indicator of a company's financial health, and a ratio of 1.34 suggests that TG Therapeutics has a relatively strong position, with more cash than debt. This is a good sign for investors.

A low Equity-to-Asset ratio of 0.33 indicates that the company has a relatively high level of debt compared to its assets. However, this doesn't necessarily mean that the company is in trouble.

Debt-to-Equity ratio of 1.32 is another way to look at a company's financial leverage. A high ratio like this suggests that the company has a lot of debt compared to its equity.

Here are some key financial ratios to consider:

The Piotroski F-Score of 1/9 suggests that the company's financial health is not very strong. The Piotroski score is a measure of nine different financial metrics, and a score of 1 or lower indicates that the company is in a distressed state.

An Altman Z-Score of 5.26 suggests that the company is in a safe financial position. The Altman score is a measure of five different financial metrics, and a score above 3 indicates that the company is unlikely to go bankrupt.

The Beneish M-Score of -0.97 suggests that the company is not likely to be involved in accounting manipulation. The Beneish score is a measure of eight different financial metrics, and a score of -1.78 or lower indicates that the company is unlikely to be involved in accounting manipulation.